key: cord-1038977-ktcz56ke authors: Nguyen, Tuan V; Frost, Steve A title: Effect of steroids on Covid-19 mortality risk: a Bayesian interpretation date: 2020-11-29 journal: Clin Infect Dis DOI: 10.1093/cid/ciaa1783 sha: 609f9dc73b6ccfb7fb69018b9c9db5fefba3425c doc_id: 1038977 cord_uid: ktcz56ke nan M a n u s c r i p t Dear Editor: In the Metcovid study, Jeronimo and colleagues conclude that methylprednisolone treatment of hospitalized patients with suspected SARS-Cov-2 infection did not reduce mortality risk [1] . This conclusion was inconsistent with the finding from the RECOVERY trial [2] which showed a 17% reduction of 28-day mortality risk associated with dexamethasone (risk ratio [RR] 0.83; 95% confidence interval [CI] 0.75 to 0.93). Here, we would like to offer an alternative interpretation of the efficacy of steroids in Covid-19 patients. The Metcovid study was based on 393 patients, much smaller than the RECOVERY trial (n = 6425 patients). Thus, a more reliable effect size can be estimated from the two studies with appropriate weight for the difference in sample sizes. We used the random-effects model [3] to synthesize the data from the studies, and found that steroids reduced the risk of 28-day mortality by 10% (RR 0.90; 95% CI, 0.83 to 0.98). A relevant question to ask is what is the probability that steroids reduce mortality risk among Covid-19 patients. This question can be addressed by a Bayesian analysis [4] which supplements the traditional inference based on P-values [5] . In the Bayesian analysis, data from an existing study are combined with prior data to derive the posterior probability of an effect, and this approach of inference has been applied in clinical trial interpretation [4, 6] . For binary outcome, prior data are often expressed in terms of a beta distribution, and likelihood of existing data is modeled as a binomial distribution, and the posterior result is a beta distribution (i.e., the beta-binomial model) [7] . Alternatively, the prior relative risk and likelihood are expressed by a normal distribution, then the resulting distribution is also a normal distribution (i.e., the normal -normal model) [8] . In the RECOVERY study, the investigators observed 428 deaths among 2104 patients on dexamethasone, and 1110 deaths among 4321 patients on usual care (control), and these data can be considered prior information. When the data from the Metcovid study (72 deaths in 194 patients on methylprednisolone, and 76 deaths in 1993 patients on usual care) were integrated with the prior information by a beta-binomial model, the posterior RR was 0.92 (95% CI, 0.84 to 0.99). Moreover, using the relative risk from the RECOVERY trial [2] as a prior information and Metcovid trial [1] as A c c e p t e d M a n u s c r i p t likelihood, the probability that methylprednisolone reduced Covid-19 mortality risk by 5% and 10% or greater is 99% and 87%, respectively (Figure 1) . Based on the meta-analysis and Bayesian consideration, we propose an alternative interpretation: in patients hospitalized with SARS-Cov-2 infection, steroids reduces the risk of 28-day mortality, but the magnitude of reduction is likely modest. Neither author has any potential conflicts of interest M a n u s c r i p t Methylprednisolone as Adjunctive Therapy for Patients Hospitalized With COVID-19 (Metcovid): A Randomised, Double-Blind, Phase IIb, Placebo-Controlled Trial Dexamethasone in Hospitalized Patients with Covid-19 -Preliminary Report Conducting meta-analyses in R with the metafor package Bayesian Analysis: A Practical Approach to Interpret Clinical Trials and Create Clinical Practice Guidelines Theory and practical use of Bayesian methods in interpreting clinical trial data: a narrative review Bayesian Interpretation of the EXCEL Trial and Other Randomized Clinical Trials of Left Main Coronary Artery Revascularization Placing trials in context using Bayesian analysis. GUSTO revisited by Reverend Bayes Prior convictions: Bayesian approaches to the analysis and interpretation of clinical megatrials A c c e p t e d M a n u s c r i p t